Article Text

Download PDFPDF
EP436 The kinetic profile and clinical implication of SCC-ag in squamous cervical cancer patients undergoing radical hysterectomy using simoa assay: a prospective observational study
  1. S Ye1,
  2. X Sun2,3,
  3. B Kang2,3,
  4. F Wu2,3,
  5. Z Zheng1,
  6. L Xiang1,
  7. J Liang2,3 and
  8. H Yang1
  1. 1Gynecologic Oncology, Fudan University Shanghai Cancer Center
  2. 2Fudan University Shanghai Cancer Center - Institute Merieux Laboratory, Cancer Institute
  3. 3BioMerieux (Shanghai) Company Limited, Shanghai, China


Introduction/Background To study the kinetic profile and clinicopathological implication of squamous cell carcinoma antigen (SCC-Ag) in cervical cancer patients who underwent radical hysterectomy by a self-developed Single Molecule Assay (Simoa) immunoassay.

Methodology We prospectively enrolled cervical cancer patients who were scheduled for surgery between 2016/04 and 2017/06. Consecutive serum samples were collected at five points: Day 0 (the day before surgery), Day 4 (post-operative day 4), Week 2–4, Month 2–4 and Month 5–7. A total of 92 patients and 352 samples were tested using Simoa, which were compared with commercially available Architect assay. The median SCC-Ag values for each time-point and kinetic profiles were analyzed. We further assessed the correlations between SCC-Ag value/profiles and clinicopathological parameters.

Results We demonstrated that Simoa was quite comparable to Architect. The median SCC-Ag value for each time-point using Simoa was 2.49ng/mL, 0.66ng/mL, 0.61ng/mL, 0.72ng/mL, 0.71ng/mL, respectively. The kinetic curve showed that the SCC-Ag levels decreased dramatically after surgery, and then stabilized and fluctuated to some extent within 6 months. Patients with some intermediate- or high-risk factors had significantly higher SCC-Ag values than those negative counterparts before surgery and within 3 months after surgery, but reach the same levels after 6 months. Furthermore, although patients with positive lymph node had sustained higher SCC-Ag values compared to those negative counterparts, similar kinetic tendencies were observed in both groups. Different from this finding, in comparison to the patients with surgery only, patients who received post-operative adjuvant treatment had significantly higher SCC-Ag values at the beginning, while no difference existed after completion of treatment.

Conclusion The user-friendly Simoa SCC-Ag assay was established for clinical setting. The SCC-Ag levels were higher in intermediate- or high-risk patients, whereas, the kinetic trend of SCC-Ag might be mainly affected by postoperative adjuvant therapy. The prognostic role needs follow-up data, which warranted further investigation.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.